Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian Network Meta-analysis (NMA)
Authors' conclusion
Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance. Personalized treatment selection based on patient characteristics is recommended.
Study context
- Population
- Adults with overweight or obesity (BMI ≥ 25 kg/m²)
- Participants
- 29,506 adults19 randomized controlled trials (RCTs)
- Comparison
- Retatrutide vs dual agonists vs GLP-1 RAs vs placebo
- Outcome
- Mean weight loss and ≥ 15% weight loss
- Follow-up
- ≥ 36 weeks
Methodological detailssubgroup and meta-regression analyses
- Subgroup and meta-regression analyses
Pooled result
As reported in the abstract
≥ 36 weeks
| Group | Value | OR for ≥ 15% weight loss |
|---|---|---|
| Retatrutide | mean −11.0 kg | 54.6 |
| Dual agonists | mean −11.0 kg | 16.4 |
| GLP-1RAs | mean −9.0 kg | 9.0 |
Value
Retatrutidemean −11.0 kg
Dual agonistsmean −11.0 kg
GLP-1RAsmean −9.0 kg
OR for ≥ 15% weight loss
Retatrutide54.6
Dual agonists16.4
GLP-1RAs9.0
Further pooled results
Meta-regression: effect of T2DM on weight loss
kg
- T2DM reduced weight loss with GLP-1RAs
- 4.338
- T2DM reduced weight loss with dual agonists
- 5.016
- Enhanced outcomes in female-dominant or high-BMI cohorts
Safety
Adverse events (AEs)
- Retatrutide had the highest AE risk
Original publication
Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring). Published 20 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →